Pediatric heart failure (PHF) carries a high mortality burden, yet the prognostic value of admission blood pressure (BP) remains poorly defined, and evidence-based thresholds for risk stratification are lacking. This retrospective, multicenter cohort study included 2545 children diagnosed with PHF upon admission across 30 Chinese centers (2013–2022). BP was standardized into age-, sex-, and height-specific percentiles. Associations with in-hospital mortality were analyzed using restricted cubic splines (RCS), machine learning covariate selection, and sensitivity analyses, stratified by sex, age, and etiology. Systolic BP (SBP) percentiles showed a U-shaped association with mortality, with the lowest risk at the 63.8th percentile. Risk increased below the 57th percentile [adjusted hazard ratio (aHR) = 1.86, 95
To compare school functioning (SF) in children with Hirschsprung disease (HSCR) versus healthy controls. A cross-sectional study of HSCR patients aged 7–14 years post-definitive surgery conducted across three Chinese centers (Oct 2024–May 2025) using a self-report survey. The survey employed three validated instruments: the SF domain of the PedsQL 4.0, the Delaware Bullying Victimization Scale and the Rintala Bowel Function Scale. After propensity-score-matching (1:1 matching, 207 vs. 207), HSCR students were found to perform significantly worse in Mathematics compared to controls (41.1
BACKGROUND:Stapokibart is a novel anti-interleukin-4 receptor α (IL-4Rα) monoclonal antibody approved for the treatment of adults with moderate-to-severe atopic dermatitis (AD). OBJECTIVES:To assess the safety, efficacy, pharmacokinetics, pharmacodynamics and immunogenicity of stapokibart in children with moderate-to-severe AD. METHODS:This was a multicentre open-label single-arm phase Ib/IIa trial (NCT06162507) involving 8 weeks of treatment and 8 weeks of follow-up. Children aged 6-11 years received subcutaneous stapokibart based on a bodyweight-tiered regimen (30-60 kg: 300 mg every 3 weeks for a total of three doses, including a 600-mg loading dose; 15-30 kg: 150 mg every 2 weeks for a total of four doses, including a 300-mg loading dose). RESULTS:Twenty-five patients (13 weighing 30-60 kg; 12 weighing 15-30 kg) received stapokibart; 68% reported mild or moderate adverse events. At week 8, 54% (n = 7/13) of those weighing 30-60 kg and 75% (n = 9/12) of those weighing 15-30 kg achieved a ≥ 75% improvement from baseline in Eczema Area and Severity Index. Stapokibart concentrations increased rapidly following the first dose, climbed further with repeated dosing and gradually declined after treatment discontinuation. Stapokibart reduced inflammatory biomarkers in both groups. No treatment-related antidrug antibodies were detected. No new safety signals emerged. CONCLUSIONS:Stapokibart shows potential in improving disease outcomes and appears to be well tolerated in children aged 6-11 years with moderate-to-severe AD. Larger controlled studies are needed to confirm long-term benefits.
Inflammatory diseases remain a major clinical challenge due to their complex pathologies and the limitations of current anti-inflammatory therapies. Conventional treatments, such as non-steroidal anti-inflammatory drugs and biologics, often provide incomplete relief and cause significant side effects, creating an urgent need for safer, more effective interventions. Plant-derived extracellular vesicles (PDEVs)—natural nanocarriers with inherent biocompatibility and cross-kingdom regulatory capacity—have emerged as a novel therapeutic approach that could address these shortcomings by safely delivering anti-inflammatory signals across species boundaries. This review examines PDEVs as both therapeutic tools and targets in inflammatory diseases, delineating their unique properties, anti-inflammatory mechanisms, and translational potential. Key topics include the biogenesis, composition, and isolation of PDEVs; their multifaceted roles in modulating immune responses; and evidence of efficacy in various models of inflammatory disease. Collectively, current findings indicate that PDEVs represent biocompatible, multi-target agents that effectively attenuate inflammation and promote tissue repair by overcoming the barriers to drug delivery and toxicity limitations of conventional therapies. Ongoing advances in omics technologies and bioengineering are expected to advance the characterization and engineering of PDEVs, fostering their integration into precision medicine approaches. Addressing challenges such as large-scale manufacturing, targeting specificity, and regulatory standardization will be crucial for translating PDEVs into safe, personalized anti-inflammatory therapies.
Systemic juvenile idiopathic arthritis (sJIA) is an autoinflammatory disorder that impacts children aged ≤ 16 years. This study evaluated the efficacy and safety of firsekibart, a fully human anti-IL-1β monoclonal antibody, in children with active sJIA. This multicenter, randomized, open-label, active-controlled phase 2 study (NCT05925452) enrolled participants aged 2– < 18 years with active sJIA across 14 sites in China. Participants were randomized (1:1:1) to firsekibart 3.0 mg/kg or 4.0 mg/kg subcutaneously every 4 weeks, or tocilizumab intravenously every 2 weeks, for 24 weeks. The primary endpoint was modified JIA American College of Rheumatology Pediatric criteria (ACR Pedi) 30 response at day 28. Secondary endpoints included ACR Pedi 30/50/70/90 responses, corticosteroid tapering, immunogenicity, and safety. Fifty participants were randomized (firsekibart 3.0 mg/kg: n = 17; 4.0 mg/kg: n = 16; tocilizumab: n = 17). At day 28, ACR Pedi 30 response rates were 94.1